Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Acquires $83,800.00 in Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz purchased 20,000 shares of the company’s stock in a transaction on Tuesday, January 24th. The stock was purchased at an average price of $4.19 per share, for a total transaction of $83,800.00. Following the purchase, the chief executive officer now directly owns 5,451,873 shares of the company’s stock, valued at approximately $22,843,347.87. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Compass Therapeutics Stock Up 10.5 %

CMPX stock opened at $4.21 on Wednesday. Compass Therapeutics, Inc. has a 12-month low of $1.25 and a 12-month high of $5.65. The company has a market cap of $531.26 million, a price-to-earnings ratio of -10.02 and a beta of 1.35. The company has a 50 day moving average of $4.69 and a two-hundred day moving average of $3.58.

Compass Therapeutics (NASDAQ:CMPX – Get Rating) last released its earnings results on Wednesday, November 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). On average, research analysts anticipate that Compass Therapeutics, Inc. will post -0.39 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in shares of Compass Therapeutics during the 3rd quarter valued at $33,000. Bank of New York Mellon Corp acquired a new stake in Compass Therapeutics in the 3rd quarter worth $55,000. Marshall Wace LLP grew its position in Compass Therapeutics by 118.4% in the 3rd quarter. Marshall Wace LLP now owns 51,816 shares of the company’s stock worth $117,000 after purchasing an additional 28,089 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Compass Therapeutics by 397.5% during the 2nd quarter. Renaissance Technologies LLC now owns 66,165 shares of the company’s stock valued at $175,000 after acquiring an additional 52,865 shares in the last quarter. Finally, Silverarc Capital Management LLC acquired a new stake in shares of Compass Therapeutics during the 3rd quarter valued at about $598,000. Institutional investors own 54.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CMPX shares. EF Hutton Acquisition Co. I started coverage on shares of Compass Therapeutics in a report on Friday, December 16th. They set a “buy” rating and a $10.30 target price for the company. Raymond James raised their target price on shares of Compass Therapeutics from $5.00 to $8.00 and gave the stock an “outperform” rating in a report on Thursday, November 10th. LADENBURG THALM/SH SH raised their price objective on shares of Compass Therapeutics to $9.00 in a research note on Wednesday, November 16th. Finally, HC Wainwright decreased their price objective on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, November 3rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $9.33.

Compass Therapeutics Company Profile

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.